The number of comorbidities a patient has can increase their risk of polypharmacy. A study of over 1.4 million patients in Scotland examined pharmacy data and comorbidities in patients with left ventricular systolic dysfunction. It found that patients with more comorbidities had higher rates of polypharmacy, rather than being related to the left ventricular systolic dysfunction diagnosis. This suggests doctors should monitor patients with multiple comorbidities more closely to reduce polypharmacy risks.